Alere i FluA*B Biologic Test Relocated in Emergency Service for Flu Diagnosis
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Study Type
Study Type
Enrollment (Actual)
Enrollment
Contacts and Locations
Study Locations
-
-
Ile-de-France
-
Paris, Ile-de-France, France, 75014
- Groupe hospitalier Paris saint Joseph
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Sampling Method
Study Population
Description
Inclusion Criteria:
- respiratory symptoms
- fever >38°C
- general symptoms of flu like pathology
Exclusion Criteria:
- cognitive disorders
- patient with guardianship
- patient already having a flu diagnosis in the last 7 days
- without social protection.
Study Plan
How is the study designed?
Design Details
- Observational Models: Cohort
- Time Perspectives: Prospective
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Time Frame |
|---|---|
|
time to have the result of the biological test
Time Frame: 3 hours
|
3 hours
|
Collaborators and Investigators
Sponsor
Sponsor
Investigators
Investigators
- Principal Investigator: GANANSIA Olivier, MD, GHPSJ
Study record dates
Study Major Dates
Study Start (Actual)
Study Start
Primary Completion (Actual)
Primary Completion
Study Completion (Actual)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Actual)
First Posted
Study Record Updates
Last Update Posted (Actual)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
Other Study ID Numbers
- TestAiFluA&B
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
product manufactured in and exported from the U.S.
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Flu
-
NCT07007377CompletedVaccination | Flu-like Symptoms | Flu-like Syndrome | FLU
-
NCT06057727CompletedFlu | Behavior, Health | Flu Vaccination
-
NCT04345549CompletedFlu Like Symptom | Flu Like Illness
-
NCT03769012CompletedStress | Flu | Cold | Flu Symptom | Cold Symptom | Gastrointestinal Tolerance | Supplement
-
NCT02188810Unknown
-
NCT05435144RecruitingCOVID-19 | Flu | Cold | Upper Respiratory Tract Infection | Flu Like Illness
-
NCT01656356Completed
-
NCT02822105Completed
Clinical Trials on Test A i Flu A&B implemented in emergency service
-
NCT06175611RecruitingSARS-CoV2 Infection | Influenza A | Respiratory Syncytial Virus (RSV) | Influenza B
-
NCT07190131CompletedInfluenza A | COVID - 19 | Influenza B
-
NCT05732610CompletedCOVID-19 | Influenza A | Influenza B
-
NCT07308158CompletedInfluenza A | COVID - 19 | RSV | Influenza B
-
NCT06928129Not yet recruitingCOVID-19 | Influenza Type B | Influenza Type A
-
NCT05268939CompletedCOVID-19 | Influenza A | RSV Infection | Influenza Type B
-
NCT05715515CompletedCOVID-19 | Influenza A | Influenza Type B
-
NCT07430410Not yet recruitingSARS-CoV-2 Infection | Influenza A | Influenza B